Pfizer's revenue fell by 42%, to $58,496 million (about €53,900 million at the current exchange rate), while net profit sank 93%. The company led by Albert Bourla has even recorded losses of 3,369 million in the fourth quarter.
Pfizer has used part of the extra income and profits derived from anti-covid products to undertake acquisitions with which to grow in the future. In December, the group closed the acquisition of Seagen, which it considers a fundamental step in its goal of achieving global leadership in oncology.